|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAB24 |
Gene summary for RAB24 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAB24 | Gene ID | 53917 |
| Gene name | RAB24, member RAS oncogene family | |
| Gene Alias | RAB24 | |
| Cytomap | 5q35.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q969Q5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 53917 | RAB24 | P42T-E | Human | Esophagus | ESCC | 1.02e-24 | 5.11e-01 | 0.1175 |
| 53917 | RAB24 | P44T-E | Human | Esophagus | ESCC | 3.07e-25 | 6.01e-01 | 0.1096 |
| 53917 | RAB24 | P47T-E | Human | Esophagus | ESCC | 3.39e-23 | 3.91e-01 | 0.1067 |
| 53917 | RAB24 | P48T-E | Human | Esophagus | ESCC | 1.03e-31 | 5.61e-01 | 0.0959 |
| 53917 | RAB24 | P49T-E | Human | Esophagus | ESCC | 1.53e-21 | 1.20e+00 | 0.1768 |
| 53917 | RAB24 | P52T-E | Human | Esophagus | ESCC | 1.39e-41 | 7.10e-01 | 0.1555 |
| 53917 | RAB24 | P54T-E | Human | Esophagus | ESCC | 1.94e-28 | 5.24e-01 | 0.0975 |
| 53917 | RAB24 | P56T-E | Human | Esophagus | ESCC | 2.55e-18 | 1.34e+00 | 0.1613 |
| 53917 | RAB24 | P57T-E | Human | Esophagus | ESCC | 3.25e-45 | 7.45e-01 | 0.0926 |
| 53917 | RAB24 | P61T-E | Human | Esophagus | ESCC | 3.31e-18 | 3.39e-01 | 0.099 |
| 53917 | RAB24 | P62T-E | Human | Esophagus | ESCC | 7.64e-75 | 1.03e+00 | 0.1302 |
| 53917 | RAB24 | P65T-E | Human | Esophagus | ESCC | 1.60e-19 | 3.65e-01 | 0.0978 |
| 53917 | RAB24 | P74T-E | Human | Esophagus | ESCC | 7.20e-35 | 7.62e-01 | 0.1479 |
| 53917 | RAB24 | P75T-E | Human | Esophagus | ESCC | 7.67e-35 | 6.26e-01 | 0.1125 |
| 53917 | RAB24 | P76T-E | Human | Esophagus | ESCC | 4.33e-38 | 7.54e-01 | 0.1207 |
| 53917 | RAB24 | P79T-E | Human | Esophagus | ESCC | 4.93e-24 | 4.09e-01 | 0.1154 |
| 53917 | RAB24 | P80T-E | Human | Esophagus | ESCC | 1.57e-53 | 1.19e+00 | 0.155 |
| 53917 | RAB24 | P82T-E | Human | Esophagus | ESCC | 4.84e-32 | 1.08e+00 | 0.1072 |
| 53917 | RAB24 | P83T-E | Human | Esophagus | ESCC | 1.11e-59 | 1.29e+00 | 0.1738 |
| 53917 | RAB24 | P84T-E | Human | Esophagus | ESCC | 3.72e-20 | 7.87e-01 | 0.0933 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAB24 | SNV | Missense_Mutation | rs146377924 | c.605N>G | p.His202Arg | p.H202R | Q969Q5 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.95) | TCGA-A2-A0EN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| RAB24 | SNV | Missense_Mutation | novel | c.213G>T | p.Glu71Asp | p.E71D | Q969Q5 | protein_coding | tolerated(0.17) | benign(0.05) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RAB24 | SNV | Missense_Mutation | c.397C>T | p.Arg133Cys | p.R133C | Q969Q5 | protein_coding | tolerated(0.05) | possibly_damaging(0.671) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| RAB24 | SNV | Missense_Mutation | rs777474622 | c.517N>A | p.Val173Ile | p.V173I | Q969Q5 | protein_coding | tolerated(0.35) | benign(0.019) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RAB24 | SNV | Missense_Mutation | c.193N>A | p.Ala65Thr | p.A65T | Q969Q5 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RAB24 | SNV | Missense_Mutation | novel | c.422A>G | p.Asp141Gly | p.D141G | Q969Q5 | protein_coding | tolerated(0.06) | benign(0.296) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RAB24 | SNV | Missense_Mutation | c.136N>A | p.Val46Met | p.V46M | Q969Q5 | protein_coding | tolerated(0.06) | possibly_damaging(0.84) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RAB24 | SNV | Missense_Mutation | c.164G>A | p.Arg55Gln | p.R55Q | Q969Q5 | protein_coding | tolerated(0.38) | benign(0.007) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| RAB24 | SNV | Missense_Mutation | novel | c.224N>T | p.Arg75Ile | p.R75I | Q969Q5 | protein_coding | deleterious(0.01) | possibly_damaging(0.876) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RAB24 | SNV | Missense_Mutation | novel | c.502G>A | p.Val168Met | p.V168M | Q969Q5 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |